Provention Bio, Inc. financial data

Industry
Pharmaceutical Preparations
Location
55 Broad Street, 2 Nd Floor, Red Bank, NJ
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2022 - Mar 29, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 326 % -52.2%
Debt-to-equity 49.6 % +180%
Return On Equity -103 % -32.5%
Return On Assets -69.1 % -4.22%
Operating Margin -994 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 94.8M shares +48%
Common Stock, Shares, Outstanding 87.7M shares +38.3%
Entity Public Float 245M USD -50%
Common Stock, Value, Issued 9K USD +50%
Weighted Average Number of Shares Outstanding, Basic 74.7M shares +18.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 12.9M USD
Research and Development Expense 75.8M USD +8.87%
General and Administrative Expense 51.1M USD +6.4%
Operating Income (Loss) -128M USD -10.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -127M USD -9.98%
Income Tax Expense (Benefit) -7.06M USD
Net Income (Loss) Attributable to Parent -114M USD +0.76%
Earnings Per Share, Basic -1.52 USD/shares +16%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 44M USD -43.7%
Marketable Securities, Current 121M USD +615%
Accounts Receivable, after Allowance for Credit Loss, Current 1.36M USD
Inventory, Net 1.23M USD
Assets, Current 175M USD +72.8%
Property, Plant and Equipment, Net 2.21M USD +9.65%
Operating Lease, Right-of-Use Asset 321K USD -13.9%
Other Assets, Noncurrent 120K USD 0%
Assets 237M USD +74.6%
Accounts Payable, Current 6.76M USD +90.7%
Accrued Liabilities, Current 20.8M USD +52.1%
Contract with Customer, Liability, Current 17.7M USD +216%
Liabilities, Current 90.4M USD +297%
Contract with Customer, Liability, Noncurrent 707K USD -53.1%
Operating Lease, Liability, Noncurrent 439K USD -25.6%
Liabilities 115M USD +362%
Accumulated Other Comprehensive Income (Loss), Net of Tax -647K USD -365%
Retained Earnings (Accumulated Deficit) -406M USD -38.9%
Stockholders' Equity Attributable to Parent 122M USD +10%
Liabilities and Equity 237M USD +74.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15M USD +8.84%
Net Cash Provided by (Used in) Financing Activities 2.15M USD -97.9%
Net Cash Provided by (Used in) Investing Activities 9.6M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 87.7M shares +38.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.28M USD -104%
Deferred Tax Assets, Valuation Allowance 125M USD +22.1%
Deferred Tax Assets, Gross 125M USD +22.1%
Operating Lease, Liability 590K USD -17.5%
Depreciation 600K USD +50%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -114M USD +0.42%
Lessee, Operating Lease, Liability, to be Paid 738K USD -23%
Property, Plant and Equipment, Gross 3.23M USD +32.7%
Operating Lease, Liability, Current 151K USD +20.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 232K USD +2.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 227K USD +2.72%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 148K USD -39.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 238K USD +2.59%
Deferred Tax Assets, Operating Loss Carryforwards 69M USD -1.54%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 41K USD -82.8%
Operating Lease, Payments 55K USD +139%
Additional Paid in Capital 528M USD +31.1%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 255K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%